TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15897444

Group type: EXPERIMENTAL
Intervention: Carotid stent placement
Number of subjects: 46

Group type: COMPARATOR
Intervention: Antithrombotic agents alone
Number of subjects: 46
Study: 12070114

Group type: EXPERIMENTAL
Intervention: Home-based intervention (HBI)
Number of subjects: 297
Study: 10463803

Group type: EXPERIMENTAL
Intervention: Alcoholics with social phobia
Number of subjects: 794

Group type: COMPARATOR
Intervention: Alcoholics without social phobia
Number of subjects: 794
Study: 7617495

Group type: EXPERIMENTAL
Intervention: APF gel
Number of subjects: 46

Group type: COMPARATOR
Intervention: APF foam
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: APF gel and foam
Number of subjects: 46
Study: 2533187

Group type: EXPERIMENTAL
Intervention: COP 1 treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 972133

Group type: EXPERIMENTAL
Intervention: Intermittent work at 28 degrees C (45% rh)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Intermittent work at 35 degrees C (65% rh)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Intermittent work at 48 degrees C (10% rh)
Number of subjects: 7
Study: 31174403

Group type: EXPERIMENTAL
Intervention: Group A: 1000 mg calcium and 800 IU cholecalciferol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Group B: 1000 mg calcium and 800 IU cholecalciferol with an additional 1 ml liquid cholecalciferol (50,000 IU) monthly
Number of subjects: 100
Study: 28129574

Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Suppression
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Reappraisal
Number of subjects: 171
Study: 26545275

Group type: EXPERIMENTAL
Intervention: Power Balance POWERUP
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Under Armour ArmourBite
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Custom mouthguard
Number of subjects: 24

Group type: COMPARATOR
Intervention: No mouthguard (control)
Number of subjects: 24
Study: 23588240

Group type: EXPERIMENTAL
Intervention: True-elimination diet + topical nifedipine and lidocaine
Number of subjects: 161

Group type: COMPARATOR
Intervention: Sham-elimination diet + topical nifedipine and lidocaine
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: DBPC challenge with cow's milk
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: DBPC challenge with wheat
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Patients who reacted to challenges
Number of subjects: 161
Study: 21439030

Group type: EXPERIMENTAL
Intervention: Enteral nutrition (n = 16)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition (n = 16)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (standard guidelines) (n = 16)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 48
Study: 20133266

Group type: EXPERIMENTAL
Intervention: fosamprenavir/ritonavir 1400 mg/100 mg once daily
Number of subjects: 214

Group type: COMPARATOR
Intervention: fosamprenavir/ritonavir 700 mg/100 mg twice daily
Number of subjects: 214
Study: 15618599

Group type: EXPERIMENTAL
Intervention: Agility training
Number of subjects: 98

Group type: COMPARATOR
Intervention: Stretching (sham exercise)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 98
Study: 10360370

Group type: EXPERIMENTAL
Intervention: Idarubicin (8 mg/m2/day on days 1, 3, and 5) combined with VP-16 (100 mg/m2/day on days 1 to 3) and cytarabine (100 mg/m2/day on days 1 to 7)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Mitoxantrone (7 mg/m2/day on days 1, 3, and 5) combined with VP-16 (100 mg/m2/day on days 1 to 3) and cytarabine (100 mg/m2/day on days 1 to 7)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Patients aged < 70 years
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Patients aged >= 70 years
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: G-CSF (5 microg/kg/day) following induction
Number of subjects: 160

Group type: COMPARATOR
Intervention: No G-CSF following induction
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Transplanted patients
Number of subjects: 160
Study: 8706174

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate nasal spray (BDNS) manufactured in Chongqing Glaxo Limited (Group A)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate nasal spray (BDNS) manufactured in Glaxo UK (Group B)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Both groups (Group A and Group B)
Number of subjects: 204
Study: 2384652

Group type: EXPERIMENTAL
Intervention: Albuterol aerosol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6122463

Group type: EXPERIMENTAL
Intervention: 160 mg oxprenolol
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 160 mg slow release oxprenolol
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 160 mg slow release oxprenolol with 0.25 mg cyclopenthiazide
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 30943910

Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids (betamethasone 12 mg, 3 mL intramuscularly)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (normal saline 3 mL IM)
Number of subjects: 0
Study: 28531883

Group type: EXPERIMENTAL
Intervention: EBUS-TBNA
Number of subjects: 253

Group type: COMPARATOR
Intervention: c-TBNA
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Staged strategy (c-TBNA followed by EBUS-TBNA if inconclusive)
Number of subjects: 253
Study: 26926544

Group type: EXPERIMENTAL
Intervention: Surgical section of the filum plus medical treatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard medical management
Number of subjects: 21
Study: 24354651

Group type: EXPERIMENTAL
Intervention: Dental prophylaxis every 3 months
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (without T2DM)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Dental prophylaxis
Number of subjects: 52
Study: 23001587

Group type: EXPERIMENTAL
Intervention: AZD9773
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18973910

Group type: EXPERIMENTAL
Intervention: Combined stimulating surface projection zone of decussation of pyramid and traditional acupuncture treatment
Number of subjects: 131

Group type: COMPARATOR
Intervention: Traditional acupuncture treatment only
Number of subjects: 131
Study: 17316441

Group type: EXPERIMENTAL
Intervention: Arthroscopic subacromial decompression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 0
Study: 15527071

Group type: EXPERIMENTAL
Intervention: Glucose administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fructose administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sucrose administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 11199947

Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg/day
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Fluoxetine (any dosage)
Number of subjects: 130
Study: 9647683

Group type: EXPERIMENTAL
Intervention: I targets (letters 'I')
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: O targets (letters 'O')
Number of subjects: 32
Study: 8004839

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amlodipine and HCTZ
Number of subjects: 0
Study: 30075491

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg oral tablets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acupressure on foot acupoints (KI-1) for 6 minutes
Number of subjects: 0
Study: 28327195

Group type: EXPERIMENTAL
Intervention: Checklist group (group A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 80
Study: 25665096

Group type: EXPERIMENTAL
Intervention: ALVAC-HIV and AIDSVAX B/E vaccination
Number of subjects: 0
Study: 23532807

Group type: EXPERIMENTAL
Intervention: Wand(®)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Sleeper One(®)
Number of subjects: 112
Study: 21961470

Group type: EXPERIMENTAL
Intervention: Telephone counseling
Number of subjects: 5477

Group type: COMPARATOR
Intervention: Written reminders (Control)
Number of subjects: 5477
Study: 19413407

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (NRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 0
Study: 17892999

Group type: EXPERIMENTAL
Intervention: Black tea (3 glasses daily for 6 months)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Water (control group, 3 glasses daily for 6 months)
Number of subjects: 31
Study: 14706203

Group type: EXPERIMENTAL
Intervention: Propofol treatment
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study: 11685384

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 17

Group type: COMPARATOR
Intervention: Clozapine and Olanzapine
Number of subjects: 17
Study: 9597025

Group type: EXPERIMENTAL
Intervention: Dietary feedback report at baseline plus brief educational materials
Number of subjects: 296

Group type: COMPARATOR
Intervention: Control group (no feedback report at baseline)
Number of subjects: 296
Study: 7888293

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 20
Study: 3211661

Group type: EXPERIMENTAL
Intervention: Protective eyewear (various models)
Number of subjects: 64

Group type: COMPARATOR
Intervention: No eyewear (control)
Number of subjects: 64
Study: 31313547

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg once daily for 4 months along with erythropoietin 6000 IU S/C and IV iron 100 mg twice weekly after each hemodialysis
Number of subjects: 30

Group type: COMPARATOR
Intervention: Erythropoietin 6000 IU S/C and IV iron 100 mg twice weekly after each hemodialysis without atorvastatin for 4 months
Number of subjects: 30
Study: 27928454

Group type: EXPERIMENTAL
Intervention: Oral sodium bicarbonate supplementation (interdialytic doses)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (no oral sodium bicarbonate supplementation, higher bicarbonate prescriptions in dialysis)
Number of subjects: 63
Study: 27965790

Group type: EXPERIMENTAL
Intervention: Intradialytic oral nutritional supplement (ONS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nutritional advice from a renal dietitian
Number of subjects: 10
Study: 23613628

Group type: COMPARATOR
Intervention: Baseline period (after diagnosis and before tumor progression)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Progression stages
Number of subjects: 110

Group type: COMPARATOR
Intervention: Baseline period
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Progression periods
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: First progression period
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Progression
Number of subjects: 110
Study: 20384749

Group type: EXPERIMENTAL
Intervention: Low-fluence Q-switched Nd:YAG laser after 8 weeks of topical TC treatment
Number of subjects: 13

Group type: COMPARATOR
Intervention: Topical triple combination (TC) cream
Number of subjects: 13
Study: 17941095

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) psychoeducational workshop
Number of subjects: 102

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 102
Study: 15916862

Group type: EXPERIMENTAL
Intervention: Web survey mode (n = 3500)
Number of subjects: 7000

Group type: COMPARATOR
Intervention: Mail survey mode (n = 3500)
Number of subjects: 7000
Study: 12590619

Group type: EXPERIMENTAL
Intervention: Sedating antidepressants (amitriptyline, imipramine, doxepin, mianserin)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nocturnal doses of sedating antidepressants (dothiepin, mianserin, mirtazapine)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nonsedating antidepressants (moclobemide, fluoxetine, paroxetine, venlafaxine, nefazodone)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combinations of nonsedating antidepressants and benzodiazepines
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Conventional tests of psychomotor performance or self‐ratings of side effects
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Antidepressants in clinical trials
Number of subjects: 10
Study: 10683095

Group type: COMPARATOR
Intervention: Control drink (0.8 g x kg(‐1) body weight of glucose)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Glutamine drink (0.8 g x kg(‐1) body weight of glucose + 0.3 g x kg(‐1) body weight of glutamine)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Wheat hydrolysate drink (0.8 g x kg(‐1) body weight of glucose + 0.3 g x kg(‐1) body weight of wheat hydrolysate)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Whey hydrolysate drink (0.8 g x kg(‐1) body weight of glucose + 0.3 g x kg(‐1) body weight of whey hydrolysate)
Number of subjects: 8
Study: 8692117

Group type: EXPERIMENTAL
Intervention: Bolus 5‐FU 600 mg/m2 plus folinic acid 300 mg/m2 day 2 to 4 with or without dipyridamole 3 x 75 mg p.o. day 1 to 5
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Bolus 5‐FU 300 to 350 mg/m2, folinic acid 200 mg/m2 and interferon 5 x 10(9) U/m2 s.c. day 1 to 5
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: PALA 250 mg/m2, MTX 250 mg/m2 day 1 and bolus FU 600 mg/m2 day 2 q day 14
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: FU 2.6 g/m2 given as 24‐h infusion plus interferon 3 x 10(9) Ul s.c.
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: FU 2.6 g/m2 given as 24‐h infusion, folinic acid 500 mg/m2 as 2‐h infusion with or without interferon 3 x 10(9) U s.c.
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Continuous infusion regimens
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Bolus regimens
Number of subjects: 174
Study: 1531467

Group type: EXPERIMENTAL
Intervention: Intraperitoneal (IP) lidocaine + intraincisional bupivacaine
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Intraincisional bupivacaine
Number of subjects: 54

Group type: COMPARATOR
Intervention: No additional drugs after general anesthesia (controls)
Number of subjects: 54
Study: 6421472

Group type: EXPERIMENTAL
Intervention: Adriamycin (doxorubicin) and cis‐diamminedichloroplatinum(II) (AP)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: AP plus hexamethylmelamine (HAP)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Both regimens (AP and HAP)
Number of subjects: 45
Study: 30975160

Group type: EXPERIMENTAL
Intervention: Call-handlers shown the degree-of-worry (DOW) on their screens
Number of subjects: 11413

Group type: COMPARATOR
Intervention: Call-handlers not shown the degree-of-worry (DOW) on their screens
Number of subjects: 11413
Study: 30365427

Group type: EXPERIMENTAL
Intervention: Test-enhanced learning (TEL) intervention with online preworkshop MCQ test (no feedback) and postworkshop MCQ test (with feedback) after a 14-day delay.
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control group receiving no pre-/posttesting.
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Self-reported changes in learning behavior, satisfaction, and efficiency of TEL.
Number of subjects: 186
Study: 26934372

Group type: EXPERIMENTAL
Intervention: Immunization coverage surveys
Number of subjects: 1181

Group type: EXPERIMENTAL
Intervention: Serologic biomarkers (IgG‐ELISA for tetanus antitoxin and Hib anti‐capsular titers)
Number of subjects: 1181
Study: 24245805

Group type: EXPERIMENTAL
Intervention: UK Resilience Programme (UKRP)
Number of subjects: 2844

Group type: COMPARATOR
Intervention: Usual school provision (control)
Number of subjects: 2844
Study: 23281758

Group type: EXPERIMENTAL
Intervention: L-threonine supplementation at 0.2%
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: L-threonine supplementation at 0.3%
Number of subjects: 576

Group type: COMPARATOR
Intervention: Control group (0% L-threonine)
Number of subjects: 576
Study: 19624730

Group type: EXPERIMENTAL
Intervention: Topical cream with Bifidobacterium longum lysate at 10% (n = 33)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control cream (n = 33)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Topical cream with Bifidobacterium longum lysate at 10%
Number of subjects: 66
Study: 17435672

Group type: EXPERIMENTAL
Intervention: Microlaparoscopy
Number of subjects: 135

Group type: COMPARATOR
Intervention: Laparoscopy
Number of subjects: 135
Study: 15279532

Group type: EXPERIMENTAL
Intervention: Theory-driven interventions
Number of subjects: 787

Group type: EXPERIMENTAL
Intervention: Sociodemographic and TPB variables
Number of subjects: 787
Study: 11378052

Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate sodium (PPS) at doses of 300 mg, 600 mg, and 900 mg daily
Number of subjects: 376
Study: 18370544

Group type: COMPARATOR
Intervention: Atenolol 50mg daily
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Perindopril 4mg daily
Number of subjects: 100
Study: 8157551

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin 500 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin 400 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral ofloxacin 400 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous ofloxacin 400 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ofloxacin
Number of subjects: 12
Study: 3410937

Group type: EXPERIMENTAL
Intervention: EE2 (100 ng/kg.day, orally)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: GH (0.15 U/kg, sc, three times weekly)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: EE2 (50 ng/kg.day)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: GH (0.09 U/kg, three times weekly)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Combined treatment with EE2 (50 ng/kg.day) and GH (0.09 U/kg, three times weekly)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: GH (0.15 U/kg, three times weekly) with EE2 (100 ng/kg.day)
Number of subjects: 39
Study: 31822740

Group type: EXPERIMENTAL
Intervention: Vision training (generic or volleyball-specific motor actions)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Traditional volleyball training
Number of subjects: 51
Study: 28252308

Group type: EXPERIMENTAL
Intervention: Utrogestan
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Crinone 8%
Number of subjects: 111
Study: 29071946

Group type: EXPERIMENTAL
Intervention: Electroacupuncture plus western medicine
Number of subjects: 68

Group type: COMPARATOR
Intervention: Western medicine only (Control)
Number of subjects: 68
Study: 24148137

Group type: EXPERIMENTAL
Intervention: web-based personalized feedback intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: control group
Number of subjects: 0
Study: 21983111

Group type: EXPERIMENTAL
Intervention: Clopidogrel and Aspirin (C+A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 0
Study: 19563287

Group type: EXPERIMENTAL
Intervention: Semilunar coronally positioned flap (SCPF)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Subepithelial connective tissue graft (SCTG)
Number of subjects: 17
Study: 17599602

Group type: EXPERIMENTAL
Intervention: Recombinant nematode anticoagulant protein c2 (rNAPc2) administered intravenously every 48 hours for a total of 1 to 3 doses (1.5 to 10 microg/kg)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Higher-dose rNAPc2 (≥7.5 microg/kg)
Number of subjects: 203

Group type: COMPARATOR
Intervention: No UFH
Number of subjects: 203

Group type: COMPARATOR
Intervention: Half-dose UFH
Number of subjects: 203
Study: 15076785

Group type: EXPERIMENTAL
Intervention: Resistance training alone (S)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Combined resistance and endurance training (SE)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Endurance training alone (E)
Number of subjects: 31
Study: 12269596

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a in RRMS (PRISMS trial)
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a in SPMS (SPECTRIMS trial)
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Depression in RRMS
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Depression in SPMS
Number of subjects: 532
Study: 10447151

Group type: EXPERIMENTAL
Intervention: Characteristics of caregivers (gender, support systems, relationship to patient)
Number of subjects: 0
Study: 7797808

Group type: EXPERIMENTAL
Intervention: Intervention diet (fat-reduced, oil-substituted diet with more fruits, vegetable soup, pulses, and crushed almonds and walnuts mixed with skim milk)
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Intervention diet
Number of subjects: 505

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 505
Study: 2150640

Group type: EXPERIMENTAL
Intervention: Isradipine 2.5 to 5.0mg twice daily
Number of subjects: 800

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 12.5 to 25mg twice daily
Number of subjects: 800
Study: 533742

Group type: EXPERIMENTAL
Intervention: Passive tilt
Number of subjects: 5
Study: 30829609

Group type: EXPERIMENTAL
Intervention: Sentinel Lymph Node Biopsy (SLNB)
Number of subjects: 200
Study: 28627376

Group type: EXPERIMENTAL
Intervention: Aerogen Pro (PRO)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aerogen Solo (SOLO)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: NIVO vibrating mesh nebulizer
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Jet nebulizers (JN)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Metered dose inhaler with AeroChamber‐MV (MDI‐AC)
Number of subjects: 60
Study: 26064976

Group type: EXPERIMENTAL
Intervention: Vinegar
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 24347438

Group type: EXPERIMENTAL
Intervention: Pamidronate
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 22075163

Group type: EXPERIMENTAL
Intervention: Family Focused Grief Therapy (FFGT) Model
Number of subjects: 74
Study: 19493182

Group type: EXPERIMENTAL
Intervention: Multiple mini-interview (MMI)
Number of subjects: 71
Study: 17526456

Group type: EXPERIMENTAL
Intervention: Clozapine + Amisulpride
Number of subjects: 56

Group type: COMPARATOR
Intervention: Clozapine + Quetiapine
Number of subjects: 56